REGENXBIO Enhances and Expands Scientific Leadership
March 28 2017 - 7:00AM
REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage
biotechnology company seeking to improve lives through the curative
potential of gene therapy based on its proprietary NAV® Technology
Platform, today announced that Olivier Danos, Ph.D., is joining
REGENXBIO in the newly created position of Chief Scientific
Officer. Dr. Danos will report to Kenneth T. Mills, REGENXBIO’s
President and Chief Executive Officer.
Dr. Danos joins REGENXBIO from Biogen Inc., where he was Senior
Vice President, Cell and Gene Therapy. At Biogen, Dr. Danos led
company efforts dedicated to identifying and developing new
technologies for gene transfer and genome engineering. Dr. Danos
also co-founded and is an executive member of the board of
directors of Lysogene, a NAV Technology Licensee focused on the
development of gene therapy product candidates for the treatment of
Mucopolysaccharidosis Type IIIA.
“Olivier brings established industry leadership and scientific
expertise in the development of gene therapies and the field of
genome engineering to REGENXBIO,” said Dr. James M. Wilson, M.D.,
Ph.D. REGENXBIO’s scientific founder and director of the University
of Pennsylvania (Penn) Gene Therapy Program. “My relationship with
Olivier can be traced back to the early stages of our careers, when
he and I shared a bench at the Whitehead laboratories. He is an
innovative scientist who has been at the forefront of the industry,
and I look forward to collaborating with him on the advancement of
scientific research at REGENXBIO.”
“We are excited to enhance the breadth and depth of our
scientific research team. Olivier and Jim are two renowned gene
therapy pioneers who have been key players in the success of the
field,” said Mr. Mills. “We look forward to leveraging Olivier’s
rich industry experience and remarkable understanding of the space,
including his work with the NAV Technology Platform, as we build a
robust clinical pipeline of gene therapy product candidates with
the goal of improving treatment options in many diseases.”
“The NAV Technology Platform has the potential to significantly
alter the course of disease and deliver enhanced health outcomes to
patients in need,” said Dr. Danos. “I am thrilled to have the
opportunity to lead scientific research at REGENXBIO as we continue
to advance this groundbreaking technology in a broad range of
diseases that are not effectively addressed by existing drug
classes.”
Prior to Biogen, Dr. Danos served as Senior Vice President,
Molecular Medicine, Synthetic Biology and Gene Regulation at Kadmon
Pharmaceuticals. Earlier in his career, Dr. Danos was Director of
the Gene Therapy Consortium of the University College of London,
Scientific Director at Genethon and Senior Director of Research at
Somatix Therapy Corporation. Dr. Danos has directed research
focused on gene therapy at the Necker - Enfants Malades Hospital in
Paris, the French National Centre for Scientific Research and the
Pasteur Institute in Paris.
Dr. Danos received a Ph.D. in Biology at the University of Paris
Diderot and the Pasteur Institute, and a Master in Science in
Genetics and Mathematics from the University of Paris Orsay. Dr.
Danos is a founding member of the European Society of Gene and Cell
Therapy.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO’s NAV® Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of product
candidates in multiple therapeutic areas.
Note Regarding Penn
Penn has licensed certain Penn-owned AAV technologies to
REGENXBIO.
Forward-Looking Statements
This press release contains “forward-looking statements,” within
the meaning of the Private Securities Litigation Reform Act of
1995, regarding, among other things, REGENXBIO’s research,
development and regulatory plans in connection with its NAV
Technology Platform and gene therapy treatments. Such
forward-looking statements are based on current expectations and
involve inherent risks and uncertainties, including factors that
could cause actual results to differ materially from those
projected by such forward-looking statements. All of REGENXBIO’s
development timelines could be subject to adjustment depending on
recruitment rate, regulatory agency review and other factors that
could delay the initiation and completion of clinical trials.
Meaningful factors which could cause actual results to differ
include, but are not limited to, the timing of enrollment,
commencement and completion of REGENXBIO’s clinical trials; the
timing and success of preclinical studies and clinical trials
conducted by REGENXBIO and its development partners; the ability to
obtain and maintain regulatory approval of REGENXBIO’s product
candidates, and the labeling for any approved products; the scope,
progress, expansion, and costs of developing and commercializing
REGENXBIO’s product candidates; REGENXBIO’s ability to obtain and
maintain intellectual property protection for REGENXBIO’s product
candidates and technology; REGENXBIO’s growth strategies;
REGENXBIO’s competition; trends and challenges in REGENXBIO’s
business and the markets in which REGENXBIO operates; REGENXBIO’s
ability to attract or retain key personnel; the size and growth of
the potential markets for REGENXBIO’s product candidates and the
ability to serve those markets; the rate and degree of market
acceptance of any of REGENXBIO’s product candidates; REGENXBIO’s
ability to establish and maintain development partnerships;
REGENXBIO’s expenses and revenue; regulatory developments in the
United States and foreign countries; the sufficiency of REGENXBIO’s
cash resources and needs for additional financing; and other
factors discussed in the “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” sections of REGENXBIO’s Annual Report on Form 10-K for
the year ended December 31, 2016. In addition to the risks
described above and in REGENXBIO’s filings with the SEC, other
unknown or unpredictable factors also could affect REGENXBIO’s
results. There can be no assurance that the actual results or
developments anticipated by REGENXBIO will be realized or, even if
substantially realized, that they will have the expected
consequences to, or effects on, REGENXBIO. Therefore, no assurance
can be given that the outcomes stated in such forward-looking
statements and estimates will be achieved.
All forward-looking statements contained in this press release
are expressly qualified by the cautionary statements contained or
referred to herein. REGENXBIO cautions investors not to rely too
heavily on the forward-looking statements REGENXBIO makes or that
are made on its behalf. These forward-looking statements speak only
as of the date of this press release (unless another date is
indicated). REGENXBIO undertakes no obligation, and specifically
declines any obligation, to publicly update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACT:
Investors
Heather Savelle, 646-395-3734
heather@argotpartners.com
Media
Laura Bagby, 312-448-8098
lbagby@6degreespr.com
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Apr 2023 to Apr 2024